| 29.53 -2.32 (-7.28%) | 05-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 36.31 |
1-year : | 40.14 |
| Resists | First : | 31.09 |
Second : | 34.37 |
| Pivot price | 30.47 |
|||
| Supports | First : | 25.79 |
Second : | 21.45 |
| MAs | MA(5) : | 31.4 |
MA(20) : | 30.6 |
| MA(100) : | 28.24  |
MA(250) : | 24.09 |
|
| MACD | MACD : | 0.9 |
Signal : | 1 |
| %K %D | K(14,3) : | 53.4 |
D(3) : | 63.7 |
| RSI | RSI(14): 48.9 |
|||
| 52-week | High : | 36.43 | Low : | 15.35 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BEAM ] has closed above bottom band by 33.5%. Bollinger Bands are 14% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.56 - 32.74 | 32.74 - 32.91 |
| Low: | 30.53 - 30.76 | 30.76 - 30.98 |
| Close: | 31.51 - 31.85 | 31.85 - 32.16 |
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Thu, 14 May 2026
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com
Wed, 13 May 2026
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 - Yahoo Finance
Wed, 13 May 2026
Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story - Seeking Alpha
Wed, 13 May 2026
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference - ChartMill
Wed, 13 May 2026
Beam Therapeutics CEO joins RBC 2026 healthcare conference in New York - Stock Titan
Tue, 12 May 2026
BEAM's Q1 loss wider than expected, revenues beat estimates - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 103 (M) |
| Shares Float | 88 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 103.2 (%) |
| Shares Short | 22,220 (K) |
| Shares Short P.Month | 21,300 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.47 |
| Profit Margin | -57.3 % |
| Operating Margin | -15.3 % |
| Return on Assets (ttm) | -18.6 % |
| Return on Equity (ttm) | -8.2 % |
| Qtrly Rev. Growth | 279.5 % |
| Gross Profit (p.s.) | -2.63 |
| Sales Per Share | 1.36 |
| EBITDA (p.s.) | -3.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -345 (M) |
| Levered Free Cash Flow | -220 (M) |
| PE Ratio | -36.46 |
| PEG Ratio | 0 |
| Price to Book value | 2.36 |
| Price to Sales | 21.71 |
| Price to Cash Flow | -8.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|